Tracy Warren

Tracy is general partner of Astarte Ventures, an early stage investment firm focused exclusively on women’s and children’s health & wellbeing. The firm has made investments in eight companies with technologies focused on women and children, including Maven, Prima-Temp, Naya Health & Madorra. Through Astarte Ventures, Tracy and her co-founders came together to form Astarte Medical to dramatically impact the lives of preterm infants. As founding CEO, she leverages her experience of serial entrepreneurship & over 15 years as a venture capitalist & early stage investor to lead strategy & fundraising. Prior to Astarte, Tracy served as general partner at Battelle Ventures & focused on investments in health & life sciences, as well as emerging energy technologies, with an emphasis on institutional-based transactions. She led investments based on technologies licensed from national laboratories & leading universities, including Princeton Univ., CA Institute of Technology, Univ. of Pennsylvania & Oak Ridge National Lab. Tracy led the firm’s investments in NuPathe (PATH; acquired by Teva Pharmaceuticals in 2014 for $140 million), BioNano Genomics, Micro Interventional Devices & SmartSynch (sold to Itron for $100 million). Leveraging her vast experience in commercializing technologies from the nation’s leading institutions, she serves on the Board of Children’s Research Institute (CRI) at Children’s National Medical Center (Washington, DC) & formerly served on the Board of Clemson University Research Foundation, & is a member of the Business Advisory Council to the Sheikh Zayed Institute for Pediatric Surgical Innovation. Tracy also provides early-stage leadership to other businesses, currently serving as an adviser & mentor to life science female entrepreneurs through Springboard Enterprises and co-chairs the Portfolia Active Aging Fund. She received her BS in Accounting and International Business from New York University & her MBA at Columbia Business School in Finance.

[Programming descriptions are generated by participants and do not necessarily reflect the opinions of SXSW.]